WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that George Elston, Chief Financial Officer of EyePoint Pharmaceuticals, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:30 p.m. ET.
A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary erodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit www.eyepointpharma.com.
Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$11.57 |
| Daily Change: | -0.03 -0.26 |
| Daily Volume: | 466,236 |
| Market Cap: | US$797.520M |
August 06, 2025 August 06, 2025 July 29, 2025 May 07, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
